Coya Therapeutics Inc News - COYA | ADVFN

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

Home
Investing
Stocks
USA
NASDAQ
Coya Therapeutics Inc (COYA)
Coya Therapeutics Inc (COYA) News

Coya Therapeutics Inc (COYA)

7.67

-0.03

(-0.39%)

Closed July 17 4:00PM

Delayed by 15 minutes

7.70

0.03

(0.39%)

After Hours: 7:59PM

Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Form 8-K - Current report

Coya Therapeutics Expands Sponsored Research Collaboration with Houston Methodist Research Institute Along with Funding from the Johnson Center for Cellular Therapeutics to Advance Regulatory T Cell Exosome Platform into the Clinic

Joint effort to leverage existing collaboration and non-dilutive grants to advance development of proprietary Treg exosome technology towards a...

Form S-3 - Registration statement under Securities Act of 1933

Coya Therapeutics Announces Publication of ALS Study in Peer-Reviewed Journal Frontiers in Neurology

Data demonstrates halting of disease progression in patients with Amyotrophic Lateral Sclerosis (ALS) at 24...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Coya Therapeutics Announces Acceptance of Peer-Reviewed Manuscript in the Medical Journal: Frontiers in Neurology

Expands on previously reported data showing the halting of disease progression in patients with ALS at six months and a corresponding reduction...

Coya Therapeutics Announces Inclusion in the MSCI USA Micro Cap Index

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance...

Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s Disease

This investigator-initiated, double-blind, placebo-controlled study (funded by the Gates Foundation and Alzheimer’s Association) evaluates the...

Form 8-K - Current report

Coya Therapeutics Announces $5 Million Strategic Investment by the Alzheimer’s Drug Discovery Foundation (ADDF)

Funds will help support the development of COYA 302 for the treatment of Frontotemporal Dementia (FTD) COYA 302’s combination therapeutic...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Coya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial Results

Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance...

1
Next

FooBarAndGrill

FooBarAndGrill 2 days ago

Coya 8K July 15
On June 14, 2024, Coya Therapeutics, Inc. (the “Company”) submitted to the U.S. Food and Drug Administration (the “FDA”) an Investigational New Drug Application (the “IND”) seeking to initiate a study entitled “Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, 24-Week Study with Additional 24-Week Open Label Extension (OLE) to Evaluate the Safety and Efficacy of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)” (the “Study”). On July 12, 2024, the Company received an email notification from the FDA stating that additional non-clinical data is required prior to the initiation of the Study. The FDA also stated that it would provide the Company with more details about what additional information it requires within the next thirty (30) days.
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001835022/000119312524178809/d762748d8k.htm

FooBarAndGrill

FooBarAndGrill 1 month ago

The WOW signal!
Prior to initiating treatment, patients were declining at an average rate of -1.1 points per month on the ALSFRS-R rating scale- At the end of 6 months of treatment, the mean rate of change on the ALSFRS-R was +0.04 points per month.

FooBarAndGrill

FooBarAndGrill 1 month ago

$COYA ALS Peer-Reviewed Publication:
https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1415106/full

FooBarAndGrill

FooBarAndGrill 1 month ago

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologic intended to enhance regulatory T cell (Treg) function, announces the acceptance of a peer-reviewed manuscript titled, “A Phase 1 Proof-of-Concept Study Evaluating Safety, Tolerability, and Biological Marker Responses with Combination Therapy of CTLA4-Ig and Interleukin-2 in Amyotrophic Lateral Sclerosis,” in the medical journal Frontiers in Neurology. A portion of the data from the manuscript was previously presented at the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference and the 2024 Society of Neuroimmune Pharmacology Conference.
https://ih.advfn.com/stock-market/NASDAQ/coya-therapeutics-COYA/stock-news/93970259/coya-therapeutics-announces-acceptance-of-peer-rev

FooBarAndGrill

FooBarAndGrill 1 month ago

Today 2 Jun is #LouGehrigDay #EndALS

FooBarAndGrill

FooBarAndGrill 2 months ago

It’s T+1 time

FooBarAndGrill

FooBarAndGrill 2 months ago

On May 17, 2024, Coya Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the Alzheimer’s Drug Discovery Foundation (the “ADDF”) for the issuance and sale in a private placement (the “Private Placement”) of 603,136 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (“Common Stock”), at a purchase price of $8.29 per share for gross proceeds to the Company of $5.0 million.
ADDF >>>> https://www.alzdiscovery.org/
8K >>>>>>> https://www.sec.gov/ix?doc=/Archives/edgar/data/0001835022/000119312524142950/d820823d8k.htm

FooBarAndGrill

FooBarAndGrill 3 months ago

Validating A Better ALS Biomarker With Coya's Fred Grossman
Fred discusses $COYA's 1H2024 plans for a IND application and the 2H2024 P2 trial.
https://www.clinicalleader.com/doc/validating-a-better-als-biomarker-with-coya-s-fred-grossman-0001

FooBarAndGrill

FooBarAndGrill 3 months ago

Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit
https://ir.coyatherapeutics.com/news/news-details/2024/Coya-Therapeutics-to-Participate-in-the-3rd-Annual-ALS-Drug-Development-Summit/default.aspx

FooBarAndGrill

FooBarAndGrill 3 months ago

And in the world of ALS.
Amylyx Pharmaceuticals said it would voluntarily remove its drug for amyotrophic lateral sclerosis from the market, a rare move that comes less than a month after a clinical trial showed its once-promising treatment for the fatal disease doesn’t work.
https://www.washingtonpost.com/business/2024/04/04/amylyx-als-drug/

FooBarAndGrill

FooBarAndGrill 4 months ago

Investing in the fight against ALS. Hosted by Schwab Network.
https://schwabnetwork.com/video/investing-in-the-fight-against-als

FooBarAndGrill

FooBarAndGrill 4 months ago

COYA 2023 10-K
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001835022/000095017024033161/coya-20231231.htm

FooBarAndGrill

FooBarAndGrill 4 months ago

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001835022/000095017024033159/coya-20240319.htm

FooBarAndGrill

FooBarAndGrill 4 months ago

Neuroimmune Pharmacology Conference Powerpoint
https://s201.q4cdn.com/307844724/files/doc_news/2024/NeuroimmunePharmacology3-12-2024-4.pdf

FooBarAndGrill

FooBarAndGrill 4 months ago

Dr. Stan Appel will be presenting during a 30-minute segment at the The 28th Society of Neuroimmune Pharmacology Conference.
March 10-13, 2024 The Francis Marion Hotel, Charleston
https://s-nip.org/documents/2024/SNIP_2024_Schedule.pdf

FooBarAndGrill

FooBarAndGrill 5 months ago

Empowering Patient Story and Coya’s Fight Against Neurodegenerative Diseases
Coya’s VP of Operations and Patient Advocacy, Daniel Barvin, had the opportunity to shed light on the world of his empowering patient story and Coya’s fight against neurodegenerative diseases in Houston for the Reel Abilities, UP Abilities event.

FooBarAndGrill

FooBarAndGrill 5 months ago

21 Feb: COYA letter to stockholders.
Today, we announce that we are further expanding the pipeline for COYA 302, adding Alzheimer’s disease (AD) to its growing list of indications
https://ih.advfn.com/stock-market/NASDAQ/coya-therapeutics-COYA/stock-news/93327358/coya-therapeutics-issues-letter-to-stockholders-hi

FooBarAndGrill

FooBarAndGrill 5 months ago

About ALS:
ALS is a progressive disease, meaning the symptoms get worse over time. The functional status of ALS patients declines about 1 point per month on average, as measured by the Revised ALS Function Rating Scale1, or ALSFRS-R, a validated tool to monitor the progression of the disease.

COYA results:
Patients' disease progression was measured using the ALSFRS-R scale. The mean scores after initiation of treatment were not statistically different compared to the score at baseline, suggesting significant amelioration in the progression of the disease over the 48-week treatment period.

https://ih.advfn.com/stock-market/NASDAQ/coya-therapeutics-COYA/stock-news/93265319/coya-therapeutics-licenses-intellectual-property-r

FooBarAndGrill

FooBarAndGrill 6 months ago

SEC Form 4's
$COYA announced small option grants (5000 shr @ $7.41) for 3 BOD members. I expect more announcements to come.

FooBarAndGrill

FooBarAndGrill 6 months ago

8K 19 Jan 2024
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001835022/000119312524010775/d732822d8k.htm
As of December 31, 2023, Coya Therapeutics, Inc. (the “Company”) had cash and cash equivalents (unaudited) of $32.6 million. In January 2024, the Company received $7.5 million from Dr. Reddy’s Laboratories Ltd. (“Dr. Reddy’s”), as required under the terms of the Development and License Agreement entered into with Dr. Reddy’s on December 5, 2023, which was previously disclosed in our Current Report on Form 8-K filed with the Securities and Exchange Commission on December 6, 2023 (the “Form 8-K”).

The Company’s cash and cash equivalents as of December 31, 2023, pro forma for receipt of the $7.5 million from Dr. Reddy’s (as if such amount was received on December 31, 2023) would be $40.1 million.

In addition, as previously disclosed in the Form 8-K, (i) upon the first Food and Drug Administration (FDA) acceptance of an investigational new drug (IND) application for COYA 302 for the treatment of amyotrophic lateral sclerosis (ALS), Dr. Reddy’s will pay the Company an additional $4.2 million, and (ii) upon dosing of the first patient in the first Phase 2 trial of COYA 302 for the treatment of ALS in the United States, Dr. Reddy’s will pay the Company an additional $4.2 million.

The Company anticipates that the IND filing will be made in the first half of 2024 and the dosing of the first patient in the first Phase 2 trial of COYA 302 for the treatment of ALS in the United States will occur in the second half of 2024.

The Company expects its cash and cash equivalents described above will be sufficient to meet its operating needs into 2026.

FooBarAndGrill

FooBarAndGrill 6 months ago

$COYA current shares in issue: 10M
A Private placement announced DEC 5 2023 added 4.4M shares + 319K warrants.
Prospectus announced today will allow those shares to trade. The 319K warrants may also be exercised.
Currently most shares are held tightly.

FooBarAndGrill

FooBarAndGrill 6 months ago

I'm not much of a predictor. And most of the shares are tightly held.
But the company does have my respect and a good outlook long term.

Sirpeter

Sirpeter 6 months ago

Where do you see the PPS heading by year end

FooBarAndGrill

FooBarAndGrill 6 months ago

Coya has a clear path towards submission of the IND application to the FDA in the second quarter of 2024, with a planned initiation of a well-controlled, double-blind clinical trial of COYA 302 in patients with ALS upon acceptance of the IND

FooBarAndGrill

FooBarAndGrill 7 months ago

Scientists solve 18-year-old mystery and find the once-elusive source of a critical T cell population
https://medicalxpress.com/news/2023-12-scientists-year-old-mystery-once-elusive-source.html

FooBarAndGrill

FooBarAndGrill 7 months ago

2023, $COYA has secured a private placement agreement plus a partnership agreement with $RDY. These two deals will provide non-dilutive financing thru 2026.

FooBarAndGrill

FooBarAndGrill 7 months ago

T-Cells are a focus of COYA research. Understanding the language is helpful.
CAR-T cells are Chimeric Antigen Receptors. (T-Cells)
Tregs are Regulatory T-Cells.
T-Cells have great potential.
‘It’s all gone’: CAR-T therapy forces autoimmune diseases into remission

FooBarAndGrill

FooBarAndGrill 7 months ago

COYA updated Pipeline.

FooBarAndGrill

FooBarAndGrill 7 months ago

$COYA $26.5M private placement.
A very newsy 8-K

FooBarAndGrill

FooBarAndGrill 7 months ago

$COYA + $RDY

New collab announced.

FooBarAndGrill

FooBarAndGrill 7 months ago

$COYA Therapeutics has posted several YT videos.
https://www.youtube.com/@coyatherapeutics7911/videos

FooBarAndGrill

FooBarAndGrill 7 months ago

Brief Hometown Houston interview with $COYA CEO Howard Berman.
https://cw39.com/news/health/new-study-at-houston-methodist-hospital-for-alzheimers-disease/

FooBarAndGrill

FooBarAndGrill 8 months ago

$COYA's web site does not provide a clear picture of on-going clinical trials. And the studies at clinicaltrials.net don't tie back to the company or COYA-301. Dear COYA, why not?
COYA 301 Phase 1 Trial NCT05821153
COYA 301 Phase 2 Trial NCT06096090

FooBarAndGrill

FooBarAndGrill 8 months ago

It's obvious $COYA is not in the hands of traders.

FooBarAndGrill

FooBarAndGrill 8 months ago

COYA trading volume:
Friday recorded 60 trades for a total volume of 3.7K
Shares in issue 10.56m

FooBarAndGrill

FooBarAndGrill 8 months ago

Coya News and events page:
https://ir.coyatherapeutics.com/news/default.aspx

FooBarAndGrill

FooBarAndGrill 8 months ago

Coya will be presenting at at the 18th International Conference on Alzheimer’s & Parkinson’s Disease in Lisbon.
Coya Announces Acceptance of Oral Presentation

FooBarAndGrill

FooBarAndGrill 8 months ago

This completed P1 trial also tested COYA 301 (not by name) Low-Dose IL-2 administered SubQ.
NCT05821153

FooBarAndGrill

FooBarAndGrill 8 months ago

Coya is associated with this P2 clinical trial:
NCT06096090
I'm not sure why COYA is not directly tagged on the page.
The drug being tested in Low-Dose IL-2 administered SubQ.

FooBarAndGrill

FooBarAndGrill 8 months ago

COYA 301 is a new formulation of an existing drug: Proleukin® (aldesleukin).
Proleukin is designed to be administered by intravenous infusion.
COYA 301 is designed to be administered by subcutaneous injection.
Subcutaneous injection is intended for slow sustained absorption.

FooBarAndGrill

FooBarAndGrill 8 months ago

COYA and other biotechs are focusing on Exosomes as a delivery mechanism.
Exosomes explained:

FooBarAndGrill

FooBarAndGrill 8 months ago

COYA Cash: $10.9M Burn: $0.9M/Month

FooBarAndGrill

FooBarAndGrill 8 months ago

COYA targets: Alzheimers and ALS

FooBarAndGrill

FooBarAndGrill 8 months ago

COYA area of expertise: Neurology

FooBarAndGrill

FooBarAndGrill 8 months ago

Welcome to the COYA stock message board. 1st test posting.

Coya Therapeutics

Build A Bear Workshop

Delayed Upgrade Clock

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions